Diabetic Foot Ulcers Treatment Market, By Product (Advance Wound Dressings, Skin Substitutes, Growth Factors, Negative Pressure Wound Therapy Devices, Other Devices), By Ulcer Type (Neuropathic Ulcers,Ischemic Ulcers, Neuro-ischemic Ulcers), By End User (Hospital, Specialty Clinics, Long Term Care Centers, Ambulatory Surgical Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023

Code : CMI1357

Pages :188

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Global Diabetic Foot Ulcers Treatment Market- Cross Sectional Analysis:

Key players are focusing on diabetic foot ulcers treatment with the new approval of the trials, which is expected to boost demand for the diabetic foot ulcers treatment market in the North America region. For instance, in November 2021, Paracrine, Inc., a biopharmaceutical company, announced that the U.S. FDA has granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Diabetic Foot Ulcers (DFUs): A Prospective, Double-blind, Multi-center, Randomized, Parallel-Group Study –The “ASCEND Trial.”.

Global Diabetic Foot Ulcers Treatment Market - Key Players

Major players operating in the global diabetic foot ulcers treatment market include 3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc.

Companies covered:

3M Healthcare, Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, Molnlycke Health Care AB, Alkem Laboratories Ltd., Healthium Medtech, Kerecis, Podimetrics, Carmell Corporation, Paracrine, Inc., VIVEX Biologics, Inc., and PolarityTE, Inc.